Anti-angiogenic therapies for metastatic colorectal cancer - Wikidata - wikimedia - TriplyDB

Anti-angiogenic therapies for metastatic colorectal cancer

Anti-angiogenic therapies for metastatic colorectal cancer

http://www.wikidata.org/entity/Q24241813

about

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Cancer concepts and principles: primer for the interventional oncologist-part II Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease Dual targeting of insulin and venus kinase Receptors of Schistosoma mansoni for novel anti-schistosome therapy Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.A systematic review of treatment guidelines for metastatic colorectal cancer Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.Role of the endothelium in inflammatory bowel diseases.An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study.Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels.Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer.Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report.Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.Targeted therapeutic agents for colorectal cancer.MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Understanding and targeting resistance to anti-angiogenic therapies.Meta-regression of treatments for metastatic colorectal cancer: Quantifying incremental benefit from 2000 to 2012.Neovascularization in tissue engineering.Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer Hypoxia-inducible factor 1, hepatocellular carcinoma and angiogenesis.Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.

P2860

Q24202199-27F1799E-94B4-4D49-930B-B90F9E60AB36 Q26824086-039BC36E-303D-4A90-978F-6D348B1812AE Q27010961-289198CA-2BF4-4527-950D-AE5301877A01 Q28084403-835BA188-7173-4DE2-8166-D471EED3A183 Q28488169-5D99EAD3-E044-44E1-8B5D-E48BE6A7B463 Q30474689-8EE4D542-81C1-48C7-8EAD-4147871BC729 Q33403798-5A20DFDB-F87A-4500-9233-CB1A3A67D9B7 Q33995028-03659D2F-BBA5-4AFB-A635-6042DBAF96B6 Q34417585-4AF2D8B4-E8BE-456D-8BE4-2AEE2C123D8E Q34579746-4C5A884F-640A-4D78-B18E-2B6D3882732C Q34623196-FDDAE1DC-FEE8-4212-B762-2591619BF1B9 Q34654605-4FBF4AF5-7B2E-43D1-A76B-F93BF334D1F5 Q34661510-E666C9CD-A73F-421C-923F-7C4F85181D36 Q34810321-F1C9593E-56E6-47B6-93FC-06572CB56376 Q34996343-7A0D1EE5-BF62-4478-99D8-08F37BE212C7 Q35354678-50603948-DDCF-49CC-9DFC-8567BB69B91B Q35584182-EC01A601-6A88-4CB6-B36A-701FE17DB591 Q35705156-125C9D0F-E958-411C-9387-D1541544A11E Q36112303-2F886E26-4C0C-4C03-950B-5E1F9225DFA7 Q36121671-E275DD61-F469-4D55-8DE2-590200428C7F Q36299126-1C052D44-64FD-4610-85E5-77C7DC81ABA0 Q36804893-6C3CF608-8735-4CFF-8BD9-48D01D9B58F3 Q36822186-9184D298-04D6-4034-8FBD-7B7EFC34A894 Q37158228-AA5F785F-6D2D-4A01-B9DB-14602CE037CE Q37185814-BC6CF445-C609-493E-ABCC-9BEE6B0E1264 Q37408810-02A40B4A-5A55-4439-9247-127688053F9F Q38133568-75699C87-27AC-470E-9A52-18915F525AED Q39398894-38428036-F667-4B43-9A60-950650D3919D Q41889561-FE2FC974-250D-4105-890D-3C1426DAD5E6 Q41947800-4CD54E25-1868-437B-A733-1A5F739EAE6F Q42580947-E884C15E-4164-434F-A430-6213BE05BAA3 Q42682716-AE013897-776E-4CA3-95B0-3D6305C0DFFC Q55064836-1860F154-CA02-4D18-842A-71088BF6EB64

P2860

Anti-angiogenic therapies for metastatic colorectal cancer

http://www.wikidata.org/entity/Q24241813

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Anti-angiogenic therapies for metastatic colorectal cancer

@ast

Anti-angiogenic therapies for metastatic colorectal cancer

@en

Anti-angiogenic therapies for metastatic colorectal cancer

@en-gb

Anti-angiogenic therapies for metastatic colorectal cancer

@nl

type

label

Anti-angiogenic therapies for metastatic colorectal cancer

@ast

Anti-angiogenic therapies for metastatic colorectal cancer

@en

Anti-angiogenic therapies for metastatic colorectal cancer

@en-gb

Anti-angiogenic therapies for metastatic colorectal cancer

@nl

prefLabel

Anti-angiogenic therapies for metastatic colorectal cancer

@ast

Anti-angiogenic therapies for metastatic colorectal cancer

@en

Anti-angiogenic therapies for metastatic colorectal cancer

@en-gb

Anti-angiogenic therapies for metastatic colorectal cancer

@nl

P1433

Q24241813-D2BF771E-8727-4767-ADF6-DE6A2791EBBD

P1476

Q24241813-9829588E-2B11-4143-95BF-5B3E06895748

P2093

Q24241813-CEE6A4FD-9544-44DA-BF35-C7F851419A19

Q24241813-D433A389-DE47-4DF5-AAA9-EF86B6421D4B

Q24241813-E29DC413-3436-4F4B-8476-157572B298CC

P2860

Q24241813-02B5CD99-2DE1-43D2-842D-1C117F958722

Q24241813-04EB956F-F09D-4AAC-B62F-599E43B21E6B

Q24241813-0812229E-6B31-479B-A414-19BFBA4699FF

Q24241813-0A45F9D5-F826-4AE8-A451-721260A84A85

Q24241813-0AB07EA2-E203-4D6E-B779-FFB10248479D

Q24241813-14E0D987-F303-4F37-81AA-8EC7E2ECFD6D

Q24241813-230EAD7A-D209-440F-913C-959173E47AD1

Q24241813-23DD47DE-36A9-47C9-A96E-FC0BB8BAD59A

Q24241813-2B0D175B-84FD-47F1-9557-FE9CE2F6B339

Q24241813-2B81AE5D-7AAB-493F-A7EA-CD6CF6DA81A2

P31

Q24241813-895D540C-D4E5-4376-AF1B-A58397B2AE35

Q24241813-b675d16f-7586-4b7b-a086-69aebcc2f340

P3181

Q24241813-C6AD947B-DE66-42C8-A48E-DD1654570D67

P356

Q24241813-08F1B3BE-B799-4E5A-9F1A-2E598F0F0B8E

P50

Q24241813-69649DE3-7DD4-4C89-91B6-BA0DBA9FFE8D

Q24241813-B3C6A949-3E2E-48B8-8C0E-C632B7BBF118

P577

Q24241813-A60AF14E-D47C-40FC-899B-04F1AAB56B63

P698

Q24241813-71027963-0206-4E55-B291-969B31301B99

P921

Q24241813-ABACEBDE-70F8-4985-AB6B-B0520CB5662A

P3181

P356

14651858.CD005392.PUB3

P1433

Cochrane Database of Systematic Reviews

P1476

Anti-angiogenic therapies for metastatic colorectal cancer

@en

P2093

Anna Dorothea ADW Wagner

http://www.w3.org/2001/XMLSchema#string

Axel AG Grothey

http://www.w3.org/2001/XMLSchema#string

Dirk Arnold

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

P31

scholarly article

P3181

3917215

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD005392.PUB3

http://www.w3.org/2001/XMLSchema#string

P50

Johannes Haerting

Susanne Unverzagt

P577

2009-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19588372

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer